X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (266) 266
Publication (30) 30
Newspaper Article (20) 20
Book / eBook (10) 10
Patent (5) 5
Dissertation (3) 3
Book Chapter (2) 2
Book Review (2) 2
Conference Proceeding (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (102) 102
index medicus (81) 81
female (76) 76
male (76) 76
middle aged (71) 71
aged (51) 51
diabetes (49) 49
type 2 diabetes (46) 46
endocrinology & metabolism (43) 43
adult (40) 40
risk factors (32) 32
diabetes mellitus, type 2 - drug therapy (31) 31
double-blind method (26) 26
research (26) 26
care and treatment (25) 25
treatment outcome (22) 22
clinical trials (21) 21
diabetes mellitus, type 2 - blood (21) 21
diabetes mellitus, type 2 - complications (20) 20
metformin (19) 19
analysis (18) 18
dosage and administration (17) 17
obesity (17) 17
saxagliptin (17) 17
adamantane - analogs & derivatives (16) 16
insulin resistance (16) 16
blood glucose - metabolism (15) 15
cardiovascular disease (15) 15
drug therapy (15) 15
hypoglycemic agents - administration & dosage (15) 15
medicine, general & internal (15) 15
mellitus (15) 15
cross-sectional studies (14) 14
abridged index medicus (13) 13
adamantane - adverse effects (13) 13
article (13) 13
atherosclerosis (13) 13
cardiac & cardiovascular systems (13) 13
complications and side effects (13) 13
dapagliflozin (13) 13
dipeptides - adverse effects (13) 13
hypoglycemia (13) 13
hypoglycemic agents - adverse effects (13) 13
hypoglycemic agents - therapeutic use (13) 13
infant (13) 13
patients (13) 13
efficacy (12) 12
glucose (12) 12
health aspects (12) 12
metabolic syndrome (12) 12
risk (12) 12
risk-factors (12) 12
safety (12) 12
follow-up studies (11) 11
management (11) 11
obesity - complications (11) 11
usage (11) 11
weight loss (11) 11
association (10) 10
cardiovascular diseases (10) 10
cardiovascular-disease (10) 10
children (10) 10
drug therapy, combination (10) 10
incidence (10) 10
infectious diseases (10) 10
medicine (10) 10
original (10) 10
blood glucose - drug effects (9) 9
blood pressure (9) 9
diabetes mellitus (9) 9
diet (9) 9
enzymes (9) 9
hypoglycemia - chemically induced (9) 9
hypoglycemic agents (9) 9
immunology (9) 9
inadequate glycemic control (9) 9
malnutrition (9) 9
medical colleges (9) 9
nutritional and metabolic diseases (9) 9
adamantane - therapeutic use (8) 8
body mass index (8) 8
cardiovascular (8) 8
cardiovascular diseases - epidemiology (8) 8
child, preschool (8) 8
dipeptides - therapeutic use (8) 8
disease (8) 8
glucosides - administration & dosage (8) 8
glycemic control (8) 8
inflammation (8) 8
insulin (8) 8
insulin - blood (8) 8
internal medicine (8) 8
metabolism (8) 8
metformin - administration & dosage (8) 8
microbiology (8) 8
physiological aspects (8) 8
type 2 diabetes mellitus (8) 8
weight-loss (8) 8
adamantane - administration & dosage (7) 7
adolescent (7) 7
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2005, Ishāʻat 2., ISBN 9698483284, 175
Book
2005, ISBN 9789698483449, 144
Book
2003, Ishāʻat 1., ISBN 9698483195, 176
Book
Journal Article
Clinical Therapeutics, ISSN 0149-2918, 2014, Volume 36, Issue 1, pp. 84 - 100.e9
Abstract Objective Dapagliflozin is a highly selective, orally active inhibitor of renal sodium-glucose cotransporter 2 that reduces hyperglycemia by... 
Internal Medicine | Medical Education | type 2 diabetes mellitus | glycemic control | SGLT2 | Asian | dapagliflozin | monotherapy | METFORMIN | EFFICACY | SGLT2 INHIBITOR | RISK | INADEQUATE GLYCEMIC CONTROL | BODY-WEIGHT | PHARMACOKINETICS | CANAGLIFLOZIN | HYPOGLYCEMIA | PHARMACOLOGY & PHARMACY | CUTOFF POINTS | Glycated Hemoglobin A - analysis | Hypoglycemic Agents - therapeutic use | Hypoglycemic Agents - pharmacokinetics | Prospective Studies | Benzhydryl Compounds | Double-Blind Method | Drug Administration Schedule | Humans | Middle Aged | Body Weight - drug effects | Male | Treatment Outcome | Glucosides - pharmacokinetics | Blood Glucose - drug effects | Asian Continental Ancestry Group | Reproductive Tract Infections - chemically induced | Glucosides - administration & dosage | Hypoglycemic Agents - administration & dosage | Urinary Tract Infections - chemically induced | Adult | Female | Glucosides - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemia - chemically induced | Type 2 diabetes | Glucose metabolism | Medical colleges | Medical research | Hyperglycemia | Physiological aspects | Clinical trials | Medicine, Experimental | Glucose | Dextrose | Diabetes therapy | Hepatitis | Disease | Womens health | Rodents | Rheumatic diseases | Values | Patient safety | Blood pressure | Diabetes | Kinases | Drug dosages
Journal Article
Journal Article
Journal Article
Vascular Health and Risk Management, ISSN 1176-6344, 2007, Volume 3, Issue 4, pp. 511 - 520
Journal Article
Diabetes Care, ISSN 0149-5992, 11/2015, Volume 38, Issue 11, pp. 2009 - 2017
OBJECTIVE To compare the efficacy and safety of treatment with dapagliflozin versus that with placebo add-on to saxagliptin plus metformin in patients whose... 
BODY-WEIGHT | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | SULFONYLUREA | PIOGLITAZONE | EFFICACY | SAFETY | CLINICAL-TRIALS | ENDOCRINOLOGY & METABOLISM | 24-WEEK | MELLITUS | INADEQUATE GLYCEMIC CONTROL | Hypoglycemia - epidemiology | Metformin - therapeutic use | Benzhydryl Compounds - administration & dosage | Humans | Middle Aged | Male | Metformin - adverse effects | Diabetes Mellitus, Type 2 - epidemiology | Benzhydryl Compounds - adverse effects | Hypoglycemic Agents - administration & dosage | Urinary Tract Infections - chemically induced | Adamantane - therapeutic use | Adult | Female | Metformin - administration & dosage | Adamantane - administration & dosage | Hypoglycemia - chemically induced | Glucosides - adverse effects | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Dipeptides - therapeutic use | Double-Blind Method | Dipeptides - adverse effects | Treatment Outcome | Blood Glucose - drug effects | Dipeptides - administration & dosage | Urinary Tract Infections - epidemiology | Drug Therapy, Combination - methods | Glucosides - administration & dosage | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Treatment outcome | Usage | Safety and security measures | Dapagliflozin | Analysis | Clinical trials | Dosage and administration | Metformin | Saxagliptin
Journal Article
American Heart Journal, ISSN 0002-8703, 2016, Volume 174, pp. 103 - 110
Exenatide once-weekly is an extended release formulation of exenatide, a glucagon-like peptide–1 receptor agonist, which can improve glycemic control, body... 
Cardiovascular | DIABETES-MELLITUS | CARDIAC & CARDIOVASCULAR SYSTEMS | RISK-FACTORS | GLUCAGON-LIKE PEPTIDE-1 | MYOCARDIAL-INFARCTION | SAFETY | RECEPTOR AGONISTS | GLUCOSE | CLINICAL-TRIALS | DISEASE | INCRETIN-BASED THERAPIES | Risk Assessment - methods | United States - epidemiology | Glucagon-Like Peptide 1 | Prognosis | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Male | Peptides - administration & dosage | Incidence | Dose-Response Relationship, Drug | Microspheres | Hypoglycemic Agents - administration & dosage | Time Factors | Injections, Subcutaneous | Cardiovascular Diseases - epidemiology | Venoms - administration & dosage | Adult | Female | Diabetes Mellitus, Type 2 - complications | Cardiovascular Diseases - etiology | Survival Rate - trends | Double-Blind Method | Drug Administration Schedule | Risk Factors | China - epidemiology | Diabetes Mellitus, Type 2 - blood | Ontario - epidemiology | Italy - epidemiology | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | United Kingdom - epidemiology | Type 2 diabetes | Hypoglycemic agents | Glucagon | Cardiac patients | Heart attack | Corporate sponsorship | Heart attacks | Research & development--R&D | Pragmatism | Cardiovascular disease | Diabetes | Pharmaceutical industry | Patients | Cholesterol
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2017, Volume 377, Issue 13, pp. 1228 - 1239
This trial, which compared once-weekly exenatide plus usual care with usual care alone in patients with type 2 diabetes with or without previous cardiovascular... 
MEDICINE, GENERAL & INTERNAL | RISK | EVENT LOWERING EXSCEL | GLUCOSE CONTROL | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Exenatide | Peptides - administration & dosage | Incidence | Cardiovascular Diseases - complications | Hypoglycemic Agents - administration & dosage | Injections, Subcutaneous | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Venoms - administration & dosage | Female | Diabetes Mellitus, Type 2 - complications | Double-Blind Method | Drug Administration Schedule | Venoms - adverse effects | Kaplan-Meier Estimate | Diabetes Mellitus, Type 2 - blood | Least-Squares Analysis | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Type 2 diabetes | Usage | Patient outcomes | Outcome and process assessment (Health Care) | Reports | Dosage and administration | Drug therapy | Observations | Myocardial infarction | Cerebral infarction | Diabetes mellitus | Pancreatitis | Amylin | Cardiovascular disease | Patients | Thyroid carcinoma | Studies | Side effects | Pancreatic carcinoma | Pancreatic cancer | Diabetes | Health risk assessment | Heart diseases | Endocrinology | Pharmaceuticals | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article